Insider Selling: POZEN Director Sells 2,500 Shares of Stock (POZN)
POZEN (NASDAQ:POZN) Director Arthur S. Kirsch sold 2,500 shares of POZEN stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $8.67, for a total value of $21,675.00. Following the completion of the sale, the director now directly owns 40,291 shares of the company’s stock, valued at approximately $349,323. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on POZN shares. Analysts at TheStreet upgraded shares of POZEN from a “sell” rating to a “hold” rating in a research note on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $9.92.
POZEN (NASDAQ:POZN) remained flat at $8.73 during trading on Friday. 186,511 shares of the company’s stock traded hands. POZEN has a one year low of $4.73 and a one year high of $9.90. The stock has a 50-day moving average of $8.54 and a 200-day moving average of $8.35. The company’s market cap is $269.4 million.
POZEN (NASDAQ:POZN) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.04) by $0.13. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $5.50 million. During the same quarter in the prior year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was up 433.5% on a year-over-year basis. On average, analysts predict that POZEN will post $0.58 earnings per share for the current fiscal year.
POZEN Inc (NASDAQ:POZN), is a pharmaceutical company focused on transforming medicine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.